ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: TKIs target the BCR-ABL protein in CML cells and typically do not influence normal cells, and they are usually associated with fewer side effects compared with chemotherapy drugs or interferon therapy [9].